386 related articles for article (PubMed ID: 18254725)
21. Protective effect of brain-derived neurotrophic factor on pancreatic islets in obese diabetic mice.
Yamanaka M; Itakura Y; Inoue T; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
Metabolism; 2006 Oct; 55(10):1286-92. PubMed ID: 16979397
[TBL] [Abstract][Full Text] [Related]
22. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets.
Del Guerra S; Marselli L; Lupi R; Boggi U; Mosca F; Benzi L; Del Prato S; Marchetti P
J Diabetes Complications; 2005; 19(1):60-4. PubMed ID: 15642492
[TBL] [Abstract][Full Text] [Related]
23. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.
Hu S
Eur J Pharmacol; 2002 May; 442(1-2):163-71. PubMed ID: 12020694
[TBL] [Abstract][Full Text] [Related]
24. Effects of miglitol, an alpha-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats.
Goda T; Suruga K; Komori A; Kuranuki S; Mochizuki K; Makita Y; Kumazawa T
Br J Nutr; 2007 Oct; 98(4):702-10. PubMed ID: 17537288
[TBL] [Abstract][Full Text] [Related]
25. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.
Mu J; Woods J; Zhou YP; Roy RS; Li Z; Zycband E; Feng Y; Zhu L; Li C; Howard AD; Moller DE; Thornberry NA; Zhang BB
Diabetes; 2006 Jun; 55(6):1695-704. PubMed ID: 16731832
[TBL] [Abstract][Full Text] [Related]
26. Repaglinide at a cellular level.
Krogsgaard Thomsen M; Bokvist K; Høy M; Buschard K; Holst JJ; Lindström P; Gromada J
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):15-8. PubMed ID: 12702003
[TBL] [Abstract][Full Text] [Related]
27. Comparison of insulinotrophic actions of nateglinide with glibenclamide dissociated from absorption in conscious dogs.
Okamoto M; Ogihara N; Kawamura W; Ebihara S; Takiguchi K; Morita T; Uchida R; Yamaguchi J; Sakai T; Okuda Y; Hayashi Y; Arakawa Y; Kikuchi M
Metabolism; 2002 May; 51(5):575-81. PubMed ID: 11979388
[TBL] [Abstract][Full Text] [Related]
28. Effects of D-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic alpha- and beta-cells: comparative study with glibenclamide.
Hirose H; Maruyama H; Seto Y; Ito K; Fujita T; Dan K; Kanda N; Saruta T; Kato R
Pharmacology; 1995 Mar; 50(3):175-81. PubMed ID: 7746834
[TBL] [Abstract][Full Text] [Related]
29. Circadian and age-dependent expression patterns of GLUT2 and glucokinase in the pancreatic beta-cell of diabetic and nondiabetic rats.
Frese T; Bazwinsky I; Mühlbauer E; Peschke E
Horm Metab Res; 2007 Aug; 39(8):567-74. PubMed ID: 17712721
[TBL] [Abstract][Full Text] [Related]
30. Effect of long-term administration of insulin and glibenclamide on pancreatic A and B cell function.
Ikeda T; Fujiyama K; Hoshino T; Takeuchi T; Mashiba H; Tominaga M
Exp Clin Endocrinol; 1990 Apr; 95(2):237-41. PubMed ID: 2114304
[TBL] [Abstract][Full Text] [Related]
31. Effect of glurenorm on immunohistochemical changes in pancreatic beta cells of rats in experimental diabetes.
Koyuturk M; Ozsoy-Sacan O; Bolkent S; Yanardag R
Indian J Exp Biol; 2005 Mar; 43(3):268-71. PubMed ID: 15816415
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of nateglinide enantiomers and their metabolites in Goto-Kakizaki rats, a model for type 2 diabetes mellitus.
Tamura M; Shiba S; Kudo N; Kawashima Y
Chirality; 2010 Jan; 22(1):92-8. PubMed ID: 19387990
[TBL] [Abstract][Full Text] [Related]
33. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
34. Ca2+-secretion coupling is impaired in diabetic Goto Kakizaki rats.
Rose T; Efendic S; Rupnik M
J Gen Physiol; 2007 Jun; 129(6):493-508. PubMed ID: 17535961
[TBL] [Abstract][Full Text] [Related]
35. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum.
Shigeto M; Katsura M; Matsuda M; Ohkuma S; Kaku K
J Pharmacol Exp Ther; 2007 Jul; 322(1):1-7. PubMed ID: 17409272
[TBL] [Abstract][Full Text] [Related]
36. Effects of 18alpha-glycyrrhizin on the pharmacodynamics and pharmacokinetics of glibenclamide in alloxan-induced diabetic rats.
Ao Y; Chen J; Yue J; Peng RX
Eur J Pharmacol; 2008 Jun; 587(1-3):330-5. PubMed ID: 18462715
[TBL] [Abstract][Full Text] [Related]
37. Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide.
Hu S; Wang S; Dunning BE
Int J Exp Diabetes Res; 2001; 2(1):63-72. PubMed ID: 12369728
[TBL] [Abstract][Full Text] [Related]
38. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
Iwase M; Nakamura U; Uchizono Y; Nohara S; Sasaki N; Sonoki K; Iida M
Eur J Pharmacol; 2005 Aug; 518(2-3):243-50. PubMed ID: 16023099
[TBL] [Abstract][Full Text] [Related]
39. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
Ikenoue T; Okazaki K; Fujitani S; Tsuchiya Y; Akiyoshi M; Maki T; Kondo N
Biol Pharm Bull; 1997 Apr; 20(4):354-9. PubMed ID: 9145209
[TBL] [Abstract][Full Text] [Related]
40. Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells.
Remedi MS; Nichols CG
PLoS Med; 2008 Oct; 5(10):e206. PubMed ID: 18959471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
